Meeting the challenges of viable delivery systems for peptide and protein pharmaceuticals

American Pharmaceutical Review

Volumn 5, Issue 4, 2002, Pages 29-36

  Davis, Stanley S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CHITOSAN; DRUG; FIBROBLAST GROWTH FACTOR; HUMAN GROWTH HORMONE; INSULIN; LIPOSOME; MICROSPHERE; NANOPARTICLE; NONIONIC SURFACTANT; OCTREOTIDE; PEPTIDE DERIVATIVE; POLYANHYDRIDE; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; POLYOXYETHYLENE; PROTEIN DERIVATIVE; STRUCTURAL PROTEIN; SUGAR; SURFACTANT; TRANSCRIPTION FACTOR AP 1; ZINC;

ANIMAL EXPERIMENT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RESEARCH; DRUG STABILITY; DRUG TRANSPORT; EMULSION; HUMAN; INJECTION; MOLECULAR WEIGHT; NONHUMAN; PHASE SEPARATION; POWDER; RAT; REVIEW; SHEEP; SPRAY DRYING; SWINE; TECHNOLOGY;

EID: 0036909496     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Jain, R K. The next frontier of molecular medicine: Delivery of therapeutics. Nature Medicine 4 655-657 (1998).
2. Editorial, Nature Biotechnology. "No payoff without delivery". 16 115 (1998).
3. Lee, V H L. Changing needs in drug delivery in the era of peptide and protein drugs in Peptide and Protein Drug Delivery, ed. V H L Lee. Marcel Dekker, Inc., New York, pp1-56, 1991.
4. Langer, R.. Drug delivery and targeting. Nature 392 5-10 (1998).
5. Baker, D E. Pegylated interferons. Rev. Gastroenterol Disord. 1 87-99 (2001).
6. Russo, P L., Harrington, G A, Spelman, D W. Needleless intravenous systems: a review. Am. J. Infect. Control 27 431-434 (1999).
7. Tobio, M., Schwendeman, S P, Guo, Y, McIver, J., Langer, R., Alonso, M.J. Improved immunogenicity of a core-coated tetanus toxoid delivery system. Vaccine 18 618-622 (1999).
8. Stevenson, C L, Tan, M M. Solution stability of salmon calcitonin at high concentration for delivery of an implantable system. J. Pept. Res. 55 129-139 (2000).
9. Patton, J.S, Platz, R.M. Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8 179-196 (1992).
10. Skyler JS, Cefalu WT, Kourides IA, Landschutz WH, Balagtas CC, Cheng SL, Gelfand RA. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357 331-335 (2001).
11. Yamamoto, A., Umemori, S., Muranishi, S. Absorption enhancement of intrapulmonary administered insulin by various absorption enhancers and protease inhibitors in rats. J. Pharm. Pharmacol. 46 14-18 (1994).
12. Illum L. The nasal route for delivery of polypeptides. In: Peptide and Protein Drug Delivery. Eds. Frokjaer, S., Christrup, L., Krogsgaard-Larsen, P., Munksgaard, Copenhagen 1990, p157-170.
13. Behl, C R, Pimplaskar H K, Sileno, A P, Xia W J, deMeireles J C, Romeo, V D. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv. Drug Del. Rev. 29 117-133 (1998).
14. Illum, L., Farraj, N F, Davis, SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11 1186-1189 (1994).
15. Dodane, V., Khan, M A, Merwin, J R. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. 182 21-32 (1999).
16. Davis, S S. Nasal Vaccines. Adv. Drug Del. Rev. 51 21-42 (2001).
17. Larsen, C., Niebuhr Jorgensen, M, Tommerup, B., Mygind, N., Dagrosa, EE, Grigoleit H G, Malerczyk, V. Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin. Eur. J. Clin. Pharmacol. 33 155-159 (1987).
18. Illum, L. Transport of drugs from the nasal cavity to the central nervous system. Review. Eur. J. Pharm. Sci. 11 1-18 (2000).
19. Frey, W H, Liu, J., Chen, X., Thorne, R G., Fawcett, R G., Ala, T A., Rahman, Y-E. Delivery of 125I-NGF to the brain via the olfactory route. Drug Del. 4 87-92 (1997).
20. Born, J., Lange, T., Kern, W., McGregor, G P., Bickel, U., Fehm, H L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5 514-516 (2002).
21. De Groot, A N., Vree, T B., Hekster, Y A., Pesman, G J., Sweep, F C., Van Dongen, P J., Van Roosmalen, J. Bioavailability and pharmacokinetics of sublingual oxytocin in mate volunteers. J. Pharm. Pharmacol. 47 571-575 (1995).
22. Modi, P., Mihic, M., Lewin, A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist(trade mark) System. Diabetes Metab. Res. Rev. 18 S38-42 (2002).
23. Owens, D R. New Horizons - alternative routes for insulin therapy. Nature Reviews 1 529-540 (2002).
24. Langkjaer, L., Brange, J., Grodsky, G M., Guy, R H. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pre-treatment. J. Control. Rel. 51 47-56 (1998).
25. Mitragotri, S., Blankschtein, D., Langer, R. Ultrasound-mediated transdermal protein delivery. Science 269 850-853 (1995).
26. Cevc, G. Transfersomes, liposomes and other liquid suspensions on the skin: permeation enhancement vesicle penetration and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 13 257-388 (1996).
27. McAllister, D V., Allen, M G, Prausnitz, M R. Microfabricated microneedles for gene and drug delivery. Ann. Rev. Biomed. Eng. 2 289-313 (2000).
28. Drewe, J., Fricker, G., Vonderscher, J., Beglinger, C. Internal absorption of octeotide: absorption enhancement by polyoxyethylene-24-cholesterol ether. Br. J. Pharmacol. 108 298-303 (1993).
29. Gwinup, G., Elias, A N., Domurat, E S. Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules. Gen. Pharmacol. 22 243-246 (1991).
30. Wilding, I I., Hirst, P., Connor, A. Development of a new engineering-based capsule for human drug absorption studies. Pharm. Sci. Technol. Today 3 385-392 (2000).
31. Sezaki, H. Mucosal penetration enhancement. J Drug Target 3 175-177 (1995).
32. Leone-Bay, A., Sato, M., Paton, D., Hunt, A H., Sarubbi, D., Carozza, M., Chou, J., McDonough, J., Baughman, R A. Oral delivery of biologically active parathyroid hormone. Pharm. Res. 18 964-970 (2000).
33. Tanaka, K., Fujita, T., Yamamoto, Y., Murakami, M., Yamamoto, A., Muranishi, S. Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochim. Biophys. Acta 1283 119-126 (1996).
34. Gordon Still, J. Development of oral insulin: progress and current status. Diabetes/metabolism Res. Rev. 18 (Suppl 1) S29-S37 (2002).
35. Nielsen, C U., Andersen, R., Brodin, B., Frokjaer, S., Taub, M E., Steffansen, B. Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line. J. Control. Rel. 76 129-138 (2001).
36. Kramer, W., Wess, G., Enhsen, A., Falk, E., Hoffmann, A., Neckermann, G., Schubert, G., Urmann, M. Modified bile acids as carriers for peptides and drugs. J. Control. Rel. 46 17-30 (1997).
37. Morris, M C, Vidal, P., Chaloin, L., Heitz, F., Divita, G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25 2730-2736 (1997).
38. Hussain, N., Jaitley, V., Florence, A T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Del. Rev. 50 107-142 (2001).
39. Oksendal, A N, Bach-Gansmo, T, Jacobsen, T F, Eide, H., Andrew, E. Oral magnetic particles. Results from clinical phase II trials in 216 patients. Acta Radiol. 34 187-193 (1993).